Novo Nordisk’s semaglutide weight-loss (Wegovy) and diabetes (Ozempic) medication are now not briefly provide, U.S. regulators stated Feb. 21, 2025, a call that’s anticipated to curtail widespread entry to cheaper copies of the favored drugs.
Steve Christo/Corbis/Getty Photographs
